Anvisa authorizes phase 3 clinical trial with proxalutamide for treatment of Covid-19

In addition to Brazil, the trials will also be conducted in Germany, Argentina, South Africa, Ukraine, Mexico, and the United States.

RIO DE JANEIRO, BRAZIL - Brazil's national health regulatory agency Anvisa authorized on Monday, 19, a clinical trial to evaluate the safety and efficacy of the drug proxalutamide in the treatment of Covid-19. The study will involve 12 volunteers from the state of Roraima and another 38 from São Paulo.

Anvisa advised that the study is a phase III, randomized, double-blind, placebo-controlled trial. The substance will be given to male outpatient participants with mild to moderate Covid-19 symptoms. There is no proof yet of the drug's effectiveness in treating covid and it should not . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?